<?xml version="1.0" encoding="UTF-8"?>
<p>Several published retrospective cohort/case series studies as well as one preliminary multicenter randomized control trial (RECOVERY trial) on the use of steroids have been presented. The results from early retrospective studies and case series on corticosteroids have been quite mixed, leading many physicians to question the role of steroid therapy in SARS-CoV-2. One study on 213 patients demonstrated that the early use of methylprednisolone (0.5-1 mg/kg/day for three days) resulted in a reduction in escalation of care, mortality, and mechanical ventilation in patients with moderate-to-severe SARS-CoV-2 pneumonia [
 <xref rid="REF35" ref-type="bibr">35</xref>]. While a retrospective review of critically-ill patients from China revealed that patients treated with methylprednisolone (median dosage of 40 mg/day for eight days) were subject to increased risk of multi-organ dysfunction and a potentially increased risk of death [
 <xref rid="REF36" ref-type="bibr">36</xref>].
</p>
